Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.
Charlotte C van RuitenDick J VeltmanMadelief WijdeveldJennifer S Ten KulveMark H H KramerMax NieuwdorpRichard G IJzermanPublished in: Diabetes, obesity & metabolism (2022)
The dapagliflozin-induced changes in brain activation may contribute to the discrepancy between observed and expected weight loss with dapagliflozin. Exenatide blunted the dapagliflozin-induced changes in brain activation, which may contribute to the additional weight loss with combined treatment.